Paper Details

  1. Home
  2. Paper Details

Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients.

Author: BettenhausenDoug, JahrausChristopher D, MalikUzma, SellittiMarguerite, St ClairWilliam H

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluates the potential of balsalazide, a 5-aminosalicylate (5-ASA) drug, to prevent or limit acute radiation-induced proctosigmoiditis (RIPS) in patients undergoing pelvic radiotherapy. The unique delivery system of balsalazide, which targets the colon with high efficiency, makes it a promising candidate for reducing RIPS.
Paper Details　
Original Abstract of the Article :
A common complication of pelvic radiotherapy (RT) is acute radiation-induced proctosigmoiditis (RIPS), for which a multitude of therapies have been tried. The 5-aminosalicylates (5-ASA), which are traditionally used to treat inflammatory bowel disease, have been tested; however, all but one prior ra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ijrobp.2005.04.032

データ提供：米国国立医学図書館（NLM）

Radiation-Induced Proctosigmoiditis: A New Approach to Prevention

Radiation therapy, while a powerful tool in cancer treatment, can sometimes have undesirable side effects. This study explores the potential of balsalazide, a medication traditionally used for inflammatory bowel disease, to prevent radiation-induced proctosigmoiditis (RIPS), a common complication of pelvic radiotherapy.

Protecting Against Radiation-Induced Side Effects

The study investigates the efficacy of balsalazide in preventing or reducing the severity of RIPS in patients undergoing radiotherapy for prostate cancer. The researchers chose balsalazide, a 5-aminosalicylate drug, due to its unique delivery system that targets the colon, where RIPS often occurs.

Reducing the Burden of Radiation Side Effects

This study suggests that balsalazide could be a promising tool for preventing or mitigating the side effects of radiation therapy in patients with prostate cancer, potentially improving their quality of life during treatment. The findings highlight the importance of considering prophylactic strategies to minimize the impact of radiation-induced side effects.

Dr.Camel's Conclusion

This research, like a resourceful traveler seeking shelter from the harsh desert sun, offers a potential solution for preventing radiation-induced proctosigmoiditis (RIPS). The study's findings suggest that balsalazide could help protect patients from this common side effect, offering a more comfortable and manageable treatment experience.
Date :
  1. Date Completed 2006-01-09
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

16099600

DOI: Digital Object Identifier

10.1016/j.ijrobp.2005.04.032

Related Literature

Article Analysis
・Effects of balsalazide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.